CTLA4 and pancreatitis: Several studies have shown that the prevalence of pancreatitis in ICIs therapy using anti-CTLA4 alone or in conjunction with nivolumab and ipilimumab is higher than that using PD-1/PD-L1 alone (Su et al., 2018; George et al., 2019; Bai et al., 2021).